Latest: FDA Approves New Biosimilar for Oncology Treatment

Exploring Adenosine A3 as a Novel Target for Trigeminal Neuropathic Pain: Marcela Romero-Reyes, DDS, PhD, FAHS

0 Mins
The director of the Brotman Facial Pain Clinic at the University of Maryland talked about emerging preclinical evidence supporting adenosine A3 receptor activation for post-traumatic trigeminal neuropathic pain. [WATCH TIME: 5 minutes]
Tags:
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago